Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Community-acquired pneumonia and acid-suppressive drugs: position statement.

Literature DB >> 16482239

Community-acquired pneumonia and acid-suppressive drugs: position statement.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2006 PMID： 16482239 PMCID： PMC2538974 DOI： 10.1155/2006/324976

Source DB: PubMed Journal: Can J Gastroenterol ISSN： 0835-7900 Impact factor: 3.522

× No keyword cloud information.

25 in total

1. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group.

Authors: J E Richter; W Bochenek
Journal: Am J Gastroenterol Date: 2000-11 Impact factor: 10.864

2. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids.

Authors: J Theisen; D Nehra; D Citron; J Johansson; J A Hagen; P F Crookes; S R DeMeester; C G Bremner; T R DeMeester; J H Peters
Journal: J Gastrointest Surg Date: 2000 Jan-Feb Impact factor: 3.452

3. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months.

Authors: N J Talley; K Lauritsen; H Tunturi-Hihnala; T Lind; B Moum; C Bang; T Schulz; T M Omland; M Delle; O Junghard
Journal: Aliment Pharmacol Ther Date: 2001-03 Impact factor: 8.171

4. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.

Authors: D A Johnson; S B Benjamin; N B Vakil; J L Goldstein; M Lamet; J Whipple; D Damico; B Hamelin
Journal: Am J Gastroenterol Date: 2001-01 Impact factor: 10.864

5. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety.

Authors: N B Vakil; R Shaker; D A Johnson; T Kovacs; R D Baerg; C Hwang; D D'Amico; B Hamelin
Journal: Aliment Pharmacol Ther Date: 2001-07 Impact factor: 8.171

Review 6. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.

Authors: L Laine; D Ahnen; C McClain; E Solcia; J H Walsh
Journal: Aliment Pharmacol Ther Date: 2000-06 Impact factor: 8.171

7. Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine.

Authors: Pierre Paré; David Armstrong; Dan Pericak; Myron Pyzyk
Journal: J Clin Gastroenterol Date: 2003-08 Impact factor: 3.062

8. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.

Authors: Philip Miner; William Orr; Joseph Filippone; Leonard Jokubaitis; Sheldon Sloan
Journal: Am J Gastroenterol Date: 2002-06 Impact factor: 10.864

Review 9. Prevention of NSAID-induced gastroduodenal ulcers.

Authors: A Rostom; C Dube; G Wells; P Tugwell; V Welch; E Jolicoeur; J McGowan
Journal: Cochrane Database Syst Rev Date: 2002

Review 10. The role of proton pump inhibitors in the management of gastroesophageal reflux disease-related asthma and chronic cough.

Authors: Toni O Kiljander
Journal: Am J Med Date: 2003-08-18 Impact factor: 4.965

3 in total